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Epidemiologia i prewencja/Epidemiology and prevention
Introduction 
Metabolic syndrome (MS) means the coexistence of
several risk factors for cardiovascular diseases (CVD) and
diabetes with a frequency higher than could result from
chance. Its definition, significance and even existence have
been the subject of many controversies. Eleven years have
passed since the first official definition of MS introduced
in 1999 by the World Health Organization (WHO) [1], which
is summarized in Table I. Its use in clinical practice is rare
because tests such as albuminuria or metabolic clamp
technique to assess insulin resistance are not readily
accessible and thus are rarely used in general practice. 
A more clinician-friendly definition was proposed by the
National Cholesterol Education Program – Adult Treatment
Panel III (NCEP-ATP III) in 2001 (Table II) [1], which does not
require special testing for glucose beyond routine clinical
assessment. Furthermore, it does not require any specific
criterion to be met. In the modified version of this definition
in 2005 the threshold for impaired fasting glucose (IFG)
was reduced from 110 to 100 mg/dl [2], which
corresponded to the modified American Diabetes
Association (ADA) [3] criteria for IFG. In the same year, the
International Diabetes Foundation (IDF) published new
criteria (Table III) [3] that again modified the ATP III
definition. They considered insulin resistance as an
essential part of MS and made abdominal obesity, which
is highly correlated with this abnormality, necessary for
diagnosis of MS. When this is present, 2 additional factors
originally listed in the ATP III definition are sufficient for
diagnosis. IDF additionally recognized and emphasized
ethnic differences in the correlation between abdominal
obesity and other MS components and the risk of CVD risk
and diabetes. Thus different thresholds for abdominal
obesity were proposed for specific populations, for example
for people of European origin ≥ 94 cm in men and ≥ 80 cm
in women, for South Asian populations ≥ 90 cm in men
and ≥ 80 cm in women, and for Japanese ≥ 85 cm for men
and ≥ 90 cm for women. 
Recently 6 major organizations – the IDF Task Force on
Epidemiology and Prevention; the National Heart, Lung,
and Blood Institute; the American Heart Association; the
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World Heart Federation; the International Atherosclerosis
Society; and the International Association for the Study of
Obesity – have joint together to propose unified criteria
for MS [4]. They suggest that there should not be an
obligatory component to diagnose MS (as suggested in
the ATP III definition) but it is necessary to use different
cut-off points for abdominal obesity regarding the
characteristics of the population (as suggested in the IDF
criteria); they underscored however that further evidence
from prospective studies is needed in the second field.
This new definition has been incorporated in the presented
Polish Forum for Prevention (PFP) [5] Guidelines on MS.
In the current consensus we refer to previous PFP
guidelines [6-12] because the assessment and treatment
of a specific component of MS is usually not significantly
different than in patients without MS. However, the
important message from these guidelines is that
recognition of one risk factor of MS should encourage
physicians to look for others. It should be underscored
that the guidelines on management of hypertension in MS
have been changed in comparison to the PFP Guidelines
on Hypertension published in 2007, which is due to the
latest Reappraisal of the European guidelines on
hypertension management [13]. 
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Central obesity defined as increased waist circumference with ethnicity specific thresholds.
Plus any two of the following factors: 
• raised TG level: ≥ 150 mg/dl (1.7 mmol/l), or specific treatment for this lipid abnormality
• reduced HDL cholesterol: < 40 mg/dl (1.0 mmol/l) in males and < 50 mg/dl (1.3 mmol/l) in females, or specific treatment for this lipid 
abnormality
• raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg, or treatment of previously diagnosed hypertension
• raised fasting plasma glucose (FPG) ≥ 100 mg/dl (5.6 mmol/l), or previously diagnosed type 2 diabetes
Table III. International Diabetes Federation definition of Metabolic Syndrome
Three of the following risk factors must be present to diagnose
metabolic syndrome:
• abdominal obesity, given as waist circumference ≥ 102 cm 
in men and ≥ 88 cm in women
• triglycerides ≥ 150 mg/dl
• HDL cholesterol
men < 40 mg/dl
women < 50 mg/dl
• blood pressure ≥ 130/≥ 85 mmHg
• fasting glucose ≥ 110 mg/dl*
Table II. National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATP III) criteria for
Metabolic Syndrome
* In the 2005 modifications of these guidelines the threshold for
impaired fasting glucose was lowered to 100 mg/dl (5.6 mmol/l).
Insulin resistance, identified by 1 of the following:
• type 2 diabetes
• impaired fasting glucose
• impaired glucose tolerance
• glucose uptake below the lowest quartile for background population under investigation under hyperinsulinaemic, euglycaemic conditions
Plus any 2 of the following:
• antihypertensive medication and/or high blood pressure (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic)
• plasma triglycerides ≥ 150 mg/dl (1.7 mmol/l)
• HDL cholesterol < 35 mg/dl (0.9 mmol/l) in men or < 39 mg/dl (1.0 mmol/l) in women
• BMI ≥ 30 kg/m2 and/or waist:hip ratio > 0.9 in men, > 0.85 in women
• urinary albumin excretion rate ≥ 20 μg/min or albumin: creatinine ratio ≥ 30 mg/g
Table I. World Health Organization (WHO) Clinical Criteria for Metabolic Syndrome
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1. Metabolic syndrome (MS) is a clinical state
characterized by clustering of several factors – central
obesity, raised blood pressure, lipid and carbohydrate
metabolism abnormalities – that increase the risk of
development and progression of cardiovascular
diseases (CVD) and diabetes.
2. Pathomechanism of MS – insulin resistance, obesity
(especially abdominal), and proinflammatory state play
the key roles. They result from interaction of
demographics, lifestyle (low physical activity, unhealthy
diet), genetic factors and environmental fetal
programming. 
3. Diagnostic criteria for MS used in clinical practice in
people ≥ 16 years old:
a. waist circumference ≥ 94 cm in men and ≥ 80 cm in
women,
b. elevated triglycerides ≥ 150 mg/dl (1.7 mmol/l) or
specific treatment for this lipid abnormality (fibrates,
nicotinic acid, high dose omega-3 fatty acids),
c. low HDL cholesterol < 40 mg/dl (< 1.0 mmol/l) in men
and < 50 mg/dl (1.3 mmol/l) in women or specific
treatment for this lipid abnormality (fibrates and
nicotinic acid),
d. raised blood pressure: systolic ≥ 130 mmHg and/or
diastolic ≥ 85 mmHg or treatment of previously
diagnosed hypertension,
e. fasting plasma glucose ≥ 100 mg/dl (5.6 mmol/l) or
treatment with hypoglycaemic drugs.
To diagnose MS ≥ 3 criteria must be fulfilled.
In children MS can be diagnosed ≥ 10 years of age when
≥ 3 of the following risk factors are present: central
obesity (waist circumference ≥ 90 pc.), triglyceride level
≥ 150 mg/dl (1.7 mmol/l), HDL cholesterol ≤ 40 mg/dl 
(1.0 mmol/l), blood pressure ≥ 130/85 mmHg and fasting
glucose ≥ 100 mg/dl (5.6 mmol/l).
4. The prevalence of MS defined according to modified
NCEP-ATP III (National Cholesterol Education Program,
Adult Treatment Panel III) criteria in the general
population of Polish adults aged 20-74 is 23% in men
and 20% in women and reaches almost 50% in older
groups. The most frequent abnormality is elevated
blood pressure (69% of men with MS and 50% of
women with MS), followed by elevated triglycerides in
men (34% of men with MS) and abdominal obesity in
women (41% of women with MS). 
5. MS increases the risk of diabetes (3-6 times), CVD
events and all-cause death (2 times). 
Cardiovascular diseases risk in persons with MS is
increased (when compared to persons without MS) in
the general population as well as in patients with
diabetes and CVD. Coexistence of other risk factors,
e.g. smoking, additionally increases the risk. MS
predisposes to early organ damage such as left
ventricle hypertrophy, microalbuminuria, arterial
stiffness, thickening of intima-media complex in carotid
arteries, and endothelial dysfunction, and promotes
the prothrombotic state, which increases the risk of
venous thrombosis and pulmonary thromboembolism.
6. Diagnosis of MS – recognition of one component of
MS is an indication for active search for other
components and assessment of total CVD risk with
classic risk scales such as SCORE charts (see the Polish
Forum for Prevention Guidelines on Cardiovascular
Risk Assessment).
In patients with MS and without diabetes the oral
glucose tolerance test should be done. Total CVD risk
in individuals with MS may be higher than estimated
by the SCORE system so it is advised to actively search
for early organ damage, whose prevalence in MS
increases (see the Polish Forum for Prevention
Guidelines
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Guidelines on Arterial Hypertension). Its identification
may change the risk category in an individual.
7. Treatment of MS is aimed at decreasing the risk of
diabetes, hypertension, organ damage and CVD risk
and should be oriented at all components of MS. The
first choice therapy is weight loss, which can be
achieved by a decrease in intake of calories (500-1000
per day) and increase in physical activity (at least 
30 min of moderate physical activity a day). The goal
is a 7-10% reduction of initial weight in 6-12 months
(see the Polish Forum for Prevention Guidelines on
Overweight and Obesity). It is indicated to modify the
diet (see the Polish Forum for Prevention Guidelines
on Diet) and to stop smoking (see the Polish Forum for
Prevention Guidelines on Smoking).
8. Hypertension in individuals with MS – in its
development, the following mechanisms connected
with obesity and insulin resistance should be
considered: increased sympathetic activity, stimulation
of the renin-angiotensin-aldosterone system, abnormal
renal sodium uptake and endothelial dysfunction.
Pharmacotherapy of hypertension is indicated when
blood pressure is ≥ 140/90 mmHg. It is indicated to
reduce blood pressure to about 130/80 mmHg.
The first choice drugs are angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers
(sartans). The second choice drugs are: calcium channel
blockers and beta blockers with vasodilative effects
(carvedilol and nebivolol). Diuretics should be used only
in low doses and in combination with other
hypotensive drugs. The use of other beta blockers and
the combination of beta blockers with diuretics should
be avoided unless there is a significant indication.
9. Atherogenic dyslipidaemia is a specific lipid abnormality
found in MS which consists of: hypertriglyceridaemia,
low HDL cholesterol concentration and presence of
small dense LDL. The treatment of dyslipidaemia in
patients with MS should follow the general rules (see
the Polish Forum for Prevention Guidelines on
Dyslipidaemia).
10. Diabetes in patients with MS – management of obese
patients with MS is based on behavioural and
pharmacological treatment. The preferred drug is
metformin used in monotherapy and in combination
with other drugs. In combination therapy acarbose can
also be used. Among the less proven classes of drugs
with potential beneficial effects in patients with MS
are glitazones and incretins (glucagon-like peptide-1
agonists and dipeptidyl-peptidase IV inhibitors).
Management with metformin should be considered in
patients with MS and pre-diabetes when non-
pharmacological intervention is not effective (see the
Polish Forum for Prevention Guidelines on Diabetes).
